Biogen (BIIB) PT Lowered to $240 at RBC Capital

July 30, 2026 8:32 AM

RBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $240.00 (from $242.00) while maintaining a Outperform rating.

No results found